India Operations
Overview
In 2009-10 we crossed the Rs. 10,000 million milestone with total sales of Rs. 10,211 million. 67% of this was contributed by our India operations.
Presence
- Diabetes
- Cardiovascular
- Vitamins / Nutritional / Minerals
- Gastro-Intestinal
- Dermatology/Cosmetology
- Gynaecology
- Paediatrics
- CNS
- Anti-Infectives
- Anti-Hemorrhoids
- Respiratory
Presence in Nutritional, Gynaecology and Respiratory segments through innovative products from partners in USA and Europe and in Cosmetology with a leading European brand.
Market standing
- Ranked 18th in the Indian pharmaceutical industry (source: Awacs October 2019).
- Leader by Rx in Diabetes & Cardiology segments.
We are the leaders in the oral anti-diabetic segment in India in terms of both prescriptions and value. It is a position we have held consistently for almost two decades. Our anti-diabetes portfolio contributes to 49% to our Indian branded sales (2018-2019).
We are also leaders in the cardiovascular disease segment in terms of prescription generation. In terms of value, we rank fourth. The cardiology portfolio contributes to 29% of our Indian branded sales (2018-2019).
We have a significant presence in dermatology and are leaders in the anti-acne segment. We have launched the Sebamed range of skin-care products from Europe.